US regulator rejects cancer drug invented in China in blow to Beijing’s biotech sector
Summit’s ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US
Summit’s ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US